TNBC
Clinical trials for TNBC explained in plain language.
Never miss a new study
Get alerted when new TNBC trials appear
Sign up with your email to follow new studies for TNBC, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New drug targets rare cancer mutation in 300-Patient trial
Disease control Recruiting nowThis study tests a new drug called PC14586 (rezatapopt) in people with advanced solid tumors that have a specific TP53 Y220C mutation. The goal is to see if the drug is safe and shrinks tumors. About 300 adults whose cancer has worsened after prior treatment will take the drug al…
Matched conditions: TNBC
Phase: PHASE1, PHASE2 • Sponsor: PMV Pharmaceuticals, Inc • Aim: Disease control
Last updated May 26, 2026 02:22 UTC
-
Last-Resort drug access opens for aggressive breast cancer patients
Disease control AVAILABLEThis program offers investigational leronlimab to adults with advanced triple-negative breast cancer who have run out of standard treatments. Participants must have stage IIIB-IV disease and cannot join a clinical trial. The goal is to provide a potential treatment option when no…
Matched conditions: TNBC
Sponsor: CytoDyn, Inc. • Aim: Disease control
Last updated May 26, 2026 02:21 UTC
-
New drug combo aims to wipe out early breast cancer before surgery
Disease control Recruiting nowThis study tests whether adding the drug ivonescimab to standard chemotherapy before surgery can improve outcomes for people with early-stage triple-negative breast cancer. About 34 participants will receive the combination every three weeks for six cycles, then undergo surgery t…
Matched conditions: TNBC
Phase: PHASE2 • Sponsor: Cedars-Sinai Medical Center • Aim: Disease control
Last updated May 22, 2026 14:03 UTC
-
New drug enzelkitug takes on advanced cancers in first human trial
Disease control Recruiting nowThis early-stage study tests a new drug, enzelkitug, given alone or with standard immunotherapy drugs, in people with advanced solid tumors that have spread or cannot be removed. The main goals are to check safety and find the right dose. About 450 adults with cancers like lung, …
Matched conditions: TNBC
Phase: PHASE1 • Sponsor: Genentech, Inc. • Aim: Disease control
Last updated May 22, 2026 13:55 UTC
-
Smart CAR t cells take aim at Hard-to-Treat cancers
Disease control Recruiting nowThis study tests a new treatment called A2B395 for adults with advanced solid tumors (like colorectal, lung, breast, and kidney cancers) that have not responded to standard therapy. The treatment uses specially engineered immune cells designed to kill cancer cells while protectin…
Matched conditions: TNBC
Phase: PHASE1, PHASE2 • Sponsor: A2 Biotherapeutics Inc. • Aim: Disease control
Last updated May 13, 2026 15:59 UTC